M E Lippman
Affiliation: University of Michigan
- Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participantsM E Lippman
Osteoporosis Research Program, Women s College Hospital, Toronto, Ontario, Canada
J Clin Oncol 19:3111-6. 2001..To test the hypothesis that risk factors related to lifetime estrogen exposure predict breast cancer incidence and to test if any subgroups experience enhanced benefit from raloxifene...
- Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer riskMarc E Lippman
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
Clin Cancer Res 12:5242-7. 2006..To assess the effect of raloxifene, indicated for osteoporosis treatment and prevention, on invasive breast cancer in subgroups of postmenopausal women defined by risk factors for breast cancer...
- Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman
Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109-0368, USA
Breast Cancer Res Treat 90:1-3. 2005
- Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesisChandan Kumar-Sinha
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Cancer Res 63:132-9. 2003..These studies characterize a molecular connection between two genes individually implicated in tumorigenesis but never linked together...
- The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistanceMatthew J Sikora
Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Breast Cancer Res Treat 115:289-96. 2009..The generation of estrogen-like steroids represents a potential mechanism of resistance to aromatase inhibitors...
- Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumorsChad J Creighton
Bioinformatics Program, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Genome Biol 7:R28. 2006..CONCLUSION: Our results provide significant validation of a widely used in vitro model of estrogen signaling as being pathologically relevant to breast cancers in vivo...
- EGFR and EGFRvIII expression in primary breast cancer and cell linesJames M Rae
Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0612, USA
Breast Cancer Res Treat 87:87-95. 2004..In contrast, EGFRwt was expressed at varying levels in the majority of samples tested. We conclude that the expression of EGFRvIII is extremely rare in breast cancer and therefore it does not contribute to the malignant phenotype...
- GREB 1 is a critical regulator of hormone dependent breast cancer growthJames M Rae
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0612, USA
Breast Cancer Res Treat 92:141-9. 2005....
- GREB1 is a novel androgen-regulated gene required for prostate cancer growthJames M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
Prostate 66:886-94. 2006..GREB1 is expressed in the prostate and its putative promoter contains potential androgen receptor (AR) response elements...
- Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitorsJames M Rae
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
Breast Cancer Res Treat 83:99-107. 2004..5 microM or less. However, higher doses (EC50's >or= 2 microM) were needed to block the growth of human tumor cell lines potentially implicating a second site of action for these compounds...
- Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samplesJames M Rae
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, 5323 Med Sci 1, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
Pharmacogenetics 13:501-7. 2003..We set out to establish genotyping methods for relevant genes from archival tumor samples and determine if fixation, processing or somatic changes in the tumor might affect our ability to identify germ-line polymorphisms...
- An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor statusMarc E Lippman
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
Trans Am Clin Climatol Assoc 119:77-90; discussion 90-2. 2008..This combined biological and informatic analysis is potentially applicable to many other cancer therapeutics...
- Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure databaseZaneta Nikolovska-Coleska
University of Michigan Comprehensive Cancer Center, Departments of Internal Medicine and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109 0934, USA
J Med Chem 47:2430-40. 2004....
- Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonistsShaomeng Wang
Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Semin Oncol 30:133-42. 2003..In this article we will provide a brief review on the strategy and recent progress in designing small-molecule antagonists targeting Bcl-2 and Bcl-X(L)...
- (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancerLiang Xu
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, 5301B Medical Science Research Building III, 1500 West Medical Center Drive, Ann Arbor, MI 48109-0640, USA
Mol Cancer Ther 4:197-205. 2005..Gossypol may improve the outcome of current prostate cancer radiotherapy and represents a promising novel anticancer regime for molecular targeted therapy of hormone-refractory prostate cancer with Bcl-2/Bcl-xL overexpression...
- A transcriptional fingerprint of estrogen in human breast cancer predicts patient survivalJianjun Yu
Bioinformatigram, The University of of Michigan Medical Center, Ann Arbor, MI 48109 USA
Neoplasia 10:79-88. 2008..Taken together, these data demonstrate the power of using cell culture systems to screen for robust gene signatures of clinical relevance...
- Development and validation of a method for using breast core needle biopsies for gene expression microarray analysesMatthew Ellis
Department of Oncology, Georgetown University School of Medicine, Washington, DC 20007, USA
Clin Cancer Res 8:1155-66. 2002..Gene expression data from these studies can be used to build accurate predictive models that separate different molecular profiles. The data establish the use and effectiveness of these approaches for future prospective studies...
- Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude miceAngus M Tester
Victorian Breast Cancer Research Consortium VBCRC Invasion and Metastasis Unit, St Vincent s Institute of Medical Research, Department of Surgery, University of Melbourne, Australia
Cancer Res 64:652-8. 2004..MMP-2 may be a useful target for breast cancer therapy when refinement of MMP inhibitors provides for MMP-specific agents...
- Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspringLeena Hilakivi-Clarke
Department of Oncology, Lombardi Cancer Center, Washington, DC 20007, USA
Clin Cancer Res 8:3601-10. 2002....
- New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARKDaniel F Hayes
Breast Cancer Res Treat 100:237-8. 2006
- Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized TrialMatthew M Poggi
Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Cancer 98:697-702. 2003..After a median potential follow-up of 18.4 years, the authors present the updated results...
- Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJennifer A Low
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889-5015, USA
J Clin Oncol 22:4067-74. 2004..CONCLUSION: Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook...
- Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patientsKenneth R Meehan
Division of Hematology and Oncology, Bone Marrow Transplant Program, Georgetown University Medical Center and the Vincent T Lombardi Cancer Center, Washington, DC 20007, USA
J Hematother Stem Cell Res 11:415-21. 2002..These results demonstrate that paclitaxel with rhG-CSF is an efficient mobilizing agent in high-risk breast cancer patients...
- Acceptability of diagnostic tests for breast cancerWenchi Liang
Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC 20007, USA
Breast Cancer Res Treat 79:199-206. 2003..To assess the acceptability of new non-invasive breast cancer diagnostic tests intended to triage women in need of biopsy...